

Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets

Type of Posting	Revision Bulletin
Posting Date	25–Mar–2016
Official Date	01–Apr–2016
Expert Committee	Chemical Medicine Monographs 6
Reason for Revision	Compliance

In accordance with the Rules and Procedures of the 2015-2020 Council of Experts, the Chemical Medicines Monographs 6 Expert Committee has revised the Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets monograph. The purpose for the revision is to add *Dissolution Test 6* for a generic product approved by FDA.

The liquid chromatographic procedure used in the *Dissolution Test 6* is based on analyses performed with Partisil 10 SCX brand of L6 column. The typical retention times for fexofenadine and pseudoephedrine are about 5 min and 8 min respectively

The Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets Revision Bulletin supersedes the currently official Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets monograph. The Revision Bulletin will be incorporated in *USP 40–NF 35*.

Should you have any questions, please contact Clydewyn M. Anthony, Ph.D (301–816–8139 or cma@usp.org)

Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets

DEFINITION

Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets contain NLT 93.0% and NMT 107.0% of the labeled amounts of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) and pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$).

IDENTIFICATION

- **A.** The retention times of the major peaks of the *Sample solution* correspond to those of the *Standard solution*, as obtained in the *Assay*.

- **B. THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST (201)**

Standard solution A: 6 mg/mL of USP Fexofenadine Hydrochloride RS in methanol

Standard solution B: 12 mg/mL of USP Pseudoephedrine Hydrochloride RS in methanol

Sample solution: Transfer the equivalent of 30 mg of fexofenadine hydrochloride and 60 mg of pseudoephedrine hydrochloride from finely powdered Tablets (NLT 4) into a suitable vessel, and add 5 mL of methanol. Cap the vessel, and shake vigorously for 2 min. Pass the resulting suspension through a suitable filter of 0.45- μ m pore size. Use the filtrate.

Adsorbent: 0.2-mm layer of HPTLC silica gel mixture. Dry the plate at 105° for 1 h before use.

Application volume: 10 μ L

Developing solvent system: Toluene, dehydrated alcohol, and ammonium hydroxide (50:45:5)

Analysis: Proceed as directed, using the *Developing solvent system*. After removal of the plate, mark the solvent front, and allow the plate to air-dry. Heat the plate at 105° until the odor of ammonia disappears (about 5 min). Allow the plate to cool, and examine under UV light at 254 nm. [NOTE—The R_f values for fexofenadine and pseudoephedrine are 0.17 and 0.39, respectively.]

Acceptance criteria: The R_f value of fexofenadine hydrochloride in the *Sample solution* is comparable to that of fexofenadine hydrochloride in *Standard solution A*. The R_f value of pseudoephedrine hydrochloride in the *Sample solution* is comparable to that of pseudoephedrine hydrochloride in *Standard solution B*.

ASSAY

- **PROCEDURE 1**

Buffer: Dissolve 6.8 g of sodium acetate and 16.22 g of sodium 1-octanesulfonate in water, and dilute with water to 1 L. Adjust with glacial acetic acid to a pH of 4.6.

Mobile phase: Methanol and *Buffer* (13:7)

Diluent: Methanol and *Buffer* (3:2)

System suitability solution: Transfer 40 mg of USP Pseudoephedrine Hydrochloride RS to a 50-mL volumetric flask. Add 5 mL of *tert*-butylhydroperoxide solution, and sonicate. Cover the flask opening with aluminum foil, and place the flask in an oven at 90° for 60 min. Remove from the oven, and allow to cool. Add 35 mL of *Mobile phase*, and cool to room temperature. Dilute with *Mobile phase* to volume. The degradation of pseudoephedrine hydrochloride by this process produces the related compound ephedrone.

Related compounds stock solution: Dissolve quantities of USP Fexofenadine Related Compound A RS and

decarboxylated degradant¹ in a volume of methanol, and dilute with *Buffer* to obtain a ratio of methanol to *Buffer* of 3:2. Dilute with *Diluent* to obtain a solution having concentrations of 0.2 mg/mL for each component.

Related compounds solution: 0.02 mg/mL each of USP Fexofenadine Related Compound A RS and decarboxylated degradant from *Related compounds stock solution* diluted with *Mobile phase*

Standard stock solution: 0.4 mg/mL of fexofenadine hydrochloride and 0.8 mg/mL of pseudoephedrine hydrochloride from USP Fexofenadine Hydrochloride RS and USP Pseudoephedrine Hydrochloride RS, respectively, in *Mobile phase*

Standard solution: Dilute 6.0 mL of the *Standard stock solution* and 15.0 mL of the *Related compounds solution* with *Mobile phase* to 50 mL to obtain a solution having known concentrations of 0.096 mg/mL of pseudoephedrine hydrochloride, 0.048 mg/mL of fexofenadine hydrochloride, 0.006 mg/mL of fexofenadine related compound A, and 0.006 mg/mL of decarboxylated degradant.

Sample stock solution: Nominally equivalent to 1.2 mg/mL of fexofenadine hydrochloride and 2.4 mg/mL of pseudoephedrine hydrochloride. To prepare, transfer NLT 10 whole Tablets to a 500-mL volumetric flask. Add 300 mL of methanol, and shake by mechanical means at high speed for 60 min. Sonicate the flask for 60 min at 40°. Add 150 mL of *Buffer*, and sonicate for 60 min at 40°. Vent the flask, and vigorously shake the flask by hand at 15-min intervals during the mechanical shaking and sonication steps. Cool to room temperature, and dilute with *Buffer* to volume to obtain a final concentration. Pass a portion of this solution through a filter of 0.45- μ m or finer pore size, and use the filtrate.

Sample solution: 0.048 mg/mL and 0.096 mg/mL of fexofenadine hydrochloride and pseudoephedrine hydrochloride, respectively, from the *Sample stock solution* diluted with *Mobile phase*. [NOTE—Alternatively, centrifuge the *Sample stock solution*, and use the supernatant to prepare the *Sample solution*. Filter the *Sample solution* before analysis.]

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm \times 5-cm; 5- μ m packing L6 connected in series to a 4.6-mm \times 25-cm; 5- μ m packing L11

Column temperature: 35°

Flow rate: 1.5 mL/min

Injection volume: 20 μ L

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for pseudoephedrine and ephedrone are 1.0 and 1.2, respectively (*System suitability solution*); and for fexofenadine, fexofenadine related compound A, and decarboxylated degradant 1.0, 1.2, and 3.1, respectively (*Standard solution*).]

Suitability requirements

Resolution: NLT 1.5 between pseudoephedrine and ephedrone, *System suitability solution*; NLT 2.0 between fexofenadine and fexofenadine related compound A, *Standard solution*

Relative standard deviation: NMT 1.0% for replicate injections based on the pseudoephedrine peak,

¹ Available from USP as USP Fexofenadine Related Compound C AS, Cat# 1270446.

2 Fexofenadine

System suitability solution; NMT 1.0% for replicate injections based on the fexofenadine peak, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*
Calculate separately the percentage of the labeled amount of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) and pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- r_U = peak response of either fexofenadine or pseudoephedrine from the *Sample solution*
 r_S = peak response of either fexofenadine or pseudoephedrine from the *Standard solution*
 C_S = concentration of either USP Fexofenadine Hydrochloride RS or USP Pseudoephedrine Hydrochloride RS in the *Standard solution* (mg/mL)
 C_U = nominal concentration of either fexofenadine hydrochloride or pseudoephedrine hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 93.0%–107.0%

- PROCEDURE 2:** Use this procedure for Tablets labeled to meet *Dissolution Test 5*.

Buffer: Dissolve 6.8 g of sodium acetate and 16.22 g of sodium 1-octanesulfonate in water, and dilute with water to 1 L. Adjust with glacial acetic acid to a pH of 4.0.

Mobile phase: Methanol and *Buffer* (13:7)

System suitability solution: Transfer 60 mg of USP Pseudoephedrine Hydrochloride RS to a 50-mL volumetric flask. Add 10 mL of hydrogen peroxide, and swirl the flask. Cover the flask opening with aluminum foil, and heat in an oven at 90° for 4 h. Add 35 mL of *Mobile phase*, and cool to room temperature. Dilute with *Mobile phase* to volume. The degradation of pseudoephedrine hydrochloride by this process produces the related compound ephedrone.

Related compounds stock solution: 0.225 mg/mL each of USP Fexofenadine Related Compound A RS and decarboxylated degradant, prepared as follows. Dissolve USP Fexofenadine Related Compound A RS and decarboxylated degradant in a volume of methanol, and dilute with *Buffer* to obtain a ratio of methanol to *Buffer* of 13:5. Dilute with *Buffer* to obtain the required concentrations of the components.

Related compounds solution: 0.0113 mg/mL each of USP Fexofenadine Related Compound A RS and decarboxylated degradant from *Related compounds stock solution* in *Mobile phase*

Standard stock solution: 0.36 mg/mL of USP Fexofenadine Hydrochloride RS and 0.48 mg/mL of USP Pseudoephedrine Hydrochloride RS in *Mobile phase*

Standard solution: 0.096 mg/mL of USP Pseudoephedrine Hydrochloride RS, 0.072 mg/mL of USP Fexofenadine Hydrochloride RS, and 0.002 mg/mL each of USP Fexofenadine Related Compound A RS and decarboxylated degradant, prepared as follows. Transfer 10 mL of *Standard stock solution* and 8 mL of *Related compounds solution* to a 50-mL volumetric flask, and dilute with *Mobile phase* to volume.

Sample stock solution: Nominally equivalent to 0.36 mg/mL of fexofenadine hydrochloride and 0.48 mg/mL of pseudoephedrine hydrochloride, prepared as follows. Crush NLT 10 Tablets into small pieces in a mortar, transfer the composite to a 500-mL volumetric flask, and add 325 mL of methanol. Shake by mechanical means for at least 30 min, and sonicate for at least an additional 35 min. Add 100 mL of *Buffer*,

sonicate for 45 min, cool to room temperature, and allow to stand for 16 h without mechanical shaking. Dilute with *Buffer* to volume. Pass a portion of this solution through a suitable filter of 0.45- μ m or finer pore size. Transfer 5 mL of the filtrate to a 50-mL volumetric flask, and dilute with *Buffer* to volume.

Sample solution: 0.072 mg/mL and 0.096 mg/mL of fexofenadine hydrochloride and pseudoephedrine hydrochloride, respectively, in *Mobile phase*, from the *Sample stock solution*

Chromatographic system

(See *Chromatography* <621>, *System Suitability*.)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm \times 5-cm; 5- μ m packing L6 connected in series to a 4.6-mm \times 25-cm; 5- μ m packing L11

Column temperature: 35°

Flow rate: 1.5 mL/min

Injection volume: 20 μ L

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 2.0 between pseudoephedrine and ephedrone, *System suitability solution*; NLT 2.0 between fexofenadine and fexofenadine related compound A, *Standard solution*

Relative standard deviation: NMT 1.0% for replicate injections based on the pseudoephedrine peak, *System suitability solution*; NMT 1.0% for replicate injections based on the fexofenadine peak, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*
Calculate separately the percentage of the labeled amount of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) and pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- r_U = peak response of either fexofenadine or pseudoephedrine from the *Sample solution*
 r_S = peak response of either fexofenadine or pseudoephedrine from the *Standard solution*
 C_S = concentration of either USP Fexofenadine Hydrochloride RS or USP Pseudoephedrine Hydrochloride RS in the *Standard solution* (mg/mL)
 C_U = nominal concentration of either fexofenadine hydrochloride or pseudoephedrine hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 93.0%–107.0%

PERFORMANCE TESTS

Change to read:

• DISSOLUTION <711>

Test 1

Medium: 0.001 N hydrochloric acid; 900 mL

Apparatus 2: 50 rpm

Times

Fexofenadine hydrochloride: 15 and 45 min

Pseudoephedrine hydrochloride: 45 min; 3, 5, and 12 h

Solution A: 7.0 mg/mL of monobasic sodium phosphate monohydrate in water. Adjust with 85% phosphoric acid to a pH of 2.00 ± 0.05 .

Mobile phase: Acetonitrile and *Solution A* (9:11)
Standard solution: Dissolve quantities of USP Fexofenadine Hydrochloride RS and USP Pseudoephedrine Hydrochloride RS in *Medium*, and dilute to obtain a solution containing known concentrations similar to those expected in the *Sample solution*. [NOTE—A small amount of methanol, NMT 0.5% of the total volume, can be used to dissolve the fexofenadine hydrochloride.]

Sample solution: Pass a portion of the solution under test through a suitable nylon filter of 0.45- μ m pore size.

Chromatographic system
 (See *Chromatography* (621), *System Suitability*.)

Mode: LC
Detector: UV 210 nm
Column: 4.6-mm \times 25-cm; packing L6
Flow rate: 1 mL/min
Injection volume: 10 μ L

System suitability
Sample: *Standard solution*

Suitability requirements
Resolution: NLT 3.0 between fexofenadine and pseudoephedrine
Tailing factor: NMT 1.5 for fexofenadine and pseudoephedrine
Relative standard deviation: NMT 2.0%

Analysis
Samples: *Standard solution* and *Sample solution*
 Calculate the percentages of the labeled amounts of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) and pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) dissolved.

Tolerances
Fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$): NLT 65% (Q) of the labeled amount is dissolved in 15 min, and NLT 80% (Q) of the labeled amount is dissolved in 45 min.
Pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$): See *Table 1*.

Table 1

Time	Amount Dissolved (%)
45 min	NMT 36
3 h	45–69
5 h	61–80
12 h	NLT 80

The percentages of the labeled amount of pseudoephedrine hydrochloride, dissolved at the times specified, conform to *Dissolution* (711), *Acceptance Table 2*.

Test 2: If the product complies with this test, the labeling indicates that the product meets USP *Dissolution Test 2*.

Medium: 0.001 N hydrochloric acid; 900 mL
Apparatus 2: 50 rpm

Times
Fexofenadine hydrochloride: 45 min
Pseudoephedrine hydrochloride: 30 min; 2, 4, and 12 h

Solution A: 2.7 mg/mL of monobasic potassium phosphate and 2.2 mg/mL of sodium 1-octanesulfonate in water. Adjust with phosphoric acid to a pH of 2.50 ± 0.05 .

Mobile phase: Methanol, acetonitrile, and *Solution A* (3:3:4)

Fexofenadine standard stock solution: Transfer 66 mg of USP Fexofenadine Hydrochloride RS to a 100-mL volumetric flask. Add 10 mL of methanol, and swirl until dissolved. Add 50 mL of *Medium*, and mix. Allow the solution to equilibrate to room temperature, and dilute with *Medium* to volume.

Pseudoephedrine standard stock solution: Transfer 66 mg of USP Pseudoephedrine Hydrochloride RS to a 100-mL volumetric flask. Add 10 mL of methanol, and swirl until dissolved. Add 50 mL of *Medium*, and mix. Allow the solution to equilibrate to room temperature, and dilute with *Medium* to volume.

Standard solution: 66 μ g/mL of USP Fexofenadine Hydrochloride RS and 132 μ g/mL of USP Pseudoephedrine Hydrochloride RS from a mixture of *Fexofenadine standard stock solution* and *Pseudoephedrine standard stock solution* diluted with *Medium*

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45- μ m pore size.

Chromatographic system
 (See *Chromatography* (621), *System Suitability*.)

Mode: LC
Detector: UV 215 nm
Column: 4.6-mm \times 25-cm; 5- μ m packing L7
Flow rate: 1.5 mL/min
Injection volume: 10 μ L

System suitability
Sample: *Standard solution*

Suitability requirements
Resolution: NLT 2.0 between fexofenadine and pseudoephedrine
Tailing factor: NMT 2.0 for fexofenadine and NMT 2.5 for pseudoephedrine
Relative standard deviation: NMT 2.0% for both peaks

Analysis
Samples: *Standard solution* and *Sample solution*
 Calculate the percentages of the labeled amounts of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) and pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) dissolved.

Tolerances
Fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$): NLT 80% (Q) of the labeled amount is dissolved in 45 min.
Pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$): See *Table 2*.

Table 2

Time	Amount Dissolved (%)
30 min	NMT 35
2 h	38–58
4 h	56–76
12 h	NLT 80

The percentages of the labeled amount of pseudoephedrine hydrochloride, dissolved at the times specified, conform to *Dissolution* (711), *Acceptance Table 2*.

Test 3: If the product complies with this test, the labeling indicates that the product meets USP *Dissolution Test 3*.

Medium: 0.001 N hydrochloric acid; 900 mL
Apparatus 2: 50 rpm

Times
Fexofenadine hydrochloride: 30 min
Pseudoephedrine hydrochloride: 0.5, 2, 4, and 12 h

4 Fexofenadine

Buffer solution: 6.64 g/L of monobasic sodium phosphate in water. Adjust with phosphoric acid to a pH of 2.50 ± 0.05 .

Mobile phase: Buffer solution and acetonitrile (3:2)

Standard solution: [NOTE—A small amount of methanol, not exceeding 0.5% of the final total volume, can be used to dissolve fexofenadine hydrochloride.] Prepare a solution in *Medium* containing known concentrations of USP Fexofenadine Hydrochloride RS and USP Pseudoephedrine Hydrochloride RS similar to those expected in the solution under test.

Sample solution: Pass a portion of the solution under test through a suitable PVDF or nylon filter of 0.45- μ m pore size.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm \times 25-cm; packing L1

Flow rate: 2.5 mL/min

Injection volume: 10 μ L

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0 for fexofenadine and pseudoephedrine

Relative standard deviation: NMT 2.0% for both peaks

Analysis

Samples: *Standard solution* and *Sample solution*
Calculate the percentages of the labeled amounts of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) and pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) dissolved.

Tolerances

Fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$): NLT 80% (Q) of the labeled amount is dissolved in 30 min.

Pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$): See *Table 3*.

Table 3

Time (h)	Amount Dissolved (%)
0.5	13–33
2	35–55
4	50–70
12	NLT 80

The percentages of the labeled amount of pseudoephedrine hydrochloride, dissolved at the times specified, conform to *Dissolution* (711), *Acceptance Table 2*.

Test 4: For products labeled with a dosing interval of 24 h. If the product complies with this test, the labeling indicates that the product meets USP *Dissolution Test 4*.

Medium: 0.001 N hydrochloric acid; 900 mL

Apparatus 2: 50 rpm

Times

Fexofenadine hydrochloride: 30 min

Pseudoephedrine hydrochloride: 3, 7, and 23 h

Determine the percentages of the labeled amounts of fexofenadine hydrochloride and pseudoephedrine hydrochloride dissolved by using the chromatographic procedure described in *Test 1*.

Tolerances

Fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$): NLT 80% (Q) of the labeled amount is dissolved in 30 min.

Pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$): See *Table 4*.

Table 4

Time (h)	Amount Dissolved (%)
3	10–30
7	35–65
23	NLT 80

The percentages of the labeled amount of pseudoephedrine hydrochloride, dissolved at the times specified, conform to *Dissolution* (711), *Acceptance Table 2*.

Test 5: For products labeled with a dosing interval of 24 h. If the product complies with this test, the labeling indicates that the product meets USP *Dissolution Test 5*.

Medium: 0.001 N hydrochloric acid; 900 mL deaerated

Apparatus 2: 50 rpm, with sinkers. [NOTE—A suitable sinker is available as catalog number CAPWST-31 from www.qia-llc.com.]

Times

Fexofenadine hydrochloride: 15 and 45 min

Pseudoephedrine hydrochloride: 3, 7, and 23 h

Buffer: 4.1 g/L of anhydrous sodium acetate in water. Adjust with glacial acetic acid to a pH of 3.6 ± 0.1 .

Mobile phase: Methanol and *Buffer* (60:40)

Standard solution: Prepare a solution in *Medium* containing 0.20 mg/mL of USP Fexofenadine Hydrochloride RS and 0.27 mg/mL of USP Pseudoephedrine Hydrochloride RS. Sonicate to dissolve.

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45- μ m pore size.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm \times 10-cm; 5- μ m packing L9

Column temperature: 40°

Flow rate: 2 mL/min

Injection volume: 50 μ L

System suitability

Sample: *Standard solution*

[NOTE—The relative retention times for fexofenadine and pseudoephedrine are 0.45 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 2.0 between fexofenadine and pseudoephedrine

Tailing factor: NMT 2.0 for fexofenadine and pseudoephedrine

Relative standard deviation: NMT 1.5% for fexofenadine and pseudoephedrine

Analysis

Samples: *Standard solution* and *Sample solution*
Calculate the concentration (C_s) of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) in the sample withdrawn from the vessel at each time point (i) shown in *Table 5*:

$$\text{Result}_i = (r_u/r_s) \times C_s$$

r_u = peak response of fexofenadine from the *Sample solution*

r_s = peak response of fexofenadine from the *Standard solution*
 C_s = concentration of USP Fexofenadine Hydrochloride RS in the *Standard solution* (mg/mL)

Calculate the percentage of the labeled amount (Q_i) of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) dissolved at each time point (i) shown in *Table 5*:

$$\text{Result}_1 = C_1 \times V \times (1/L) \times 100$$

$$\text{Result}_2 = \{[C_2 \times (V - V_3)] + (C_1 \times V_3)\} \times (1/L) \times 100$$

C_i = concentration of fexofenadine hydrochloride in the portion of sample withdrawn at time point (i) (mg/mL)
 V = volume of the *Medium*, 900 mL
 L = label claim for fexofenadine hydrochloride (mg/Tablet)
 V_3 = volume of the *Sample solution* withdrawn from the *Medium* (mL)

Calculate the concentration (C_i) of pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) in the sample withdrawn from the vessel at each time point (i) shown in *Table 6*:

$$\text{Result}_i = (r_u/r_s) \times C_s$$

r_u = peak response of pseudoephedrine from the *Sample solution*
 r_s = peak response of pseudoephedrine from the *Standard solution*
 C_s = concentration of USP Pseudoephedrine Hydrochloride RS in the *Standard solution* (mg/mL)

Calculate the percentage of the labeled amount (Q_i) of pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) dissolved at each time point (i) shown in *Table 6*:

$$\text{Result}_1 = C_1 \times V \times (1/L) \times 100$$

$$\text{Result}_2 = \{[C_2 \times (V - V_3)] + (C_1 \times V_3)\} \times (1/L) \times 100$$

$$\text{Result}_3 = \{[C_3 \times [V - (2 \times V_3)]] + [(C_2 + C_1) \times V_3]\} \times (1/L) \times 100$$

C_i = concentration of pseudoephedrine hydrochloride in the portion of sample withdrawn at time point (i) (mg/mL)
 V = volume of the *Medium*, 900 mL
 L = label claim for pseudoephedrine hydrochloride (mg/Tablet)
 V_3 = volume of the *Sample solution* withdrawn from the *Medium* (mL)

Tolerances

Fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$): See *Table 5*.

Table 5

Time point (<i>i</i>)	Time (min)	Amount Dissolved (%)
1	15	NLT 60 (Q)
2	45	NLT 75 (Q)

Pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$): See *Table 6*.

Table 6

Time point (<i>i</i>)	Time (h)	Amount Dissolved (%)
1	3	10–34
2	7	35–68
3	23	NLT 80

The percentages of the labeled amount of pseudoephedrine hydrochloride, dissolved at the times specified, conform to *Dissolution* (711), *Acceptance Table 2*.

• **Test 6:** If the product complies with this test, the labeling indicates that the product meets USP *Dissolution Test 6*.

Medium: 0.001 N hydrochloric acid; 900 mL

Apparatus 2: 50 rpm

Times

Fexofenadine hydrochloride: 45 min

Pseudoephedrine hydrochloride: 30 min; 2, 4, and 12 h

Solution A: 7 g/L of monobasic sodium phosphate in water. Adjust with 85% phosphoric acid to a pH of 2.00

Mobile phase: Acetonitrile and *Solution A* (45:55)

Standard solution: 0.07 mg/mL of USP Fexofenadine Hydrochloride RS and 0.13 mg/mL of USP Pseudoephedrine Hydrochloride RS, prepared as follows. Dissolve appropriate quantities of USP Fexofenadine Hydrochloride RS and USP Pseudoephedrine Hydrochloride RS in a small amount of methanol, NMT 0.8% of the final volume, and add 40% of the final volume of *Medium*. Sonicate to dissolve and dilute with *Medium* to volume.

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45- μ m pore size.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm \times 25-cm; 10- μ m packing L6

Flow rate: 1 mL/min

Injection volume: 10 μ L

System suitability

Sample: *Standard solution*

Suitability requirements

Resolution: NLT 3.0 between fexofenadine and pseudoephedrine peaks

Tailing factor: NMT 2.0 for both fexofenadine and pseudoephedrine peaks

Relative standard deviation: NMT 2.0% for both peaks

Analysis

Samples: *Standard solution* and *Sample solution*
 Calculate the percentage of the labeled amount of fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$) dissolved:

$$\text{Result} = (r_u/r_s) \times C_s \times V \times (1/L) \times 100$$

r_u = peak response of fexofenadine from the *Sample solution*

r_s = peak response of fexofenadine from the *Standard solution*

C_s = concentration of USP Fexofenadine Hydrochloride RS in the *Standard solution* (mg/mL)

V = volume of the *Medium*, 900 mL

L = label claim for fexofenadine hydrochloride (mg/Tablet)

6 Fexofenadine

Calculate the concentration (C_i) of pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) in the sample withdrawn from the vessel at each time point (i) shown in *Table 7*:

$$\text{Result}_i = (r_u/r_s) \times C_s$$

r_u = peak response of pseudoephedrine from the *Sample solution*

r_s = peak response of pseudoephedrine from the *Standard solution*

C_s = concentration of USP Pseudoephedrine Hydrochloride RS in the *Standard solution* (mg/mL)

Calculate the percentage of the labeled amount of pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$) dissolved at each time point (i) shown in *Table 7*:

$$\text{Result}_1 = C_i \times V \times (1/L) \times 100$$

$$\text{Result}_2 = \{[C_2 \times (V - V_s)] + (C_1 \times V_s)\} \times (1/L) \times 100$$

$$\text{Result}_3 = \{(C_3 \times [V - (2 \times V_s)]) + [(C_2 + C_1) \times V_s]\} \times (1/L) \times 100$$

$$\text{Result}_4 = \{(C_4 \times [V - (3 \times V_s)]) + [(C_3 + C_2 + C_1) \times V_s]\} \times (1/L) \times 100$$

C_i = concentration of pseudoephedrine hydrochloride in the portion of sample withdrawn at time point (i) (mg/mL)

V = volume of the *Medium*, 900 mL

L = label claim for pseudoephedrine hydrochloride (mg/Tablet)

V_s = volume of the *Sample solution* withdrawn from the *Medium* (mL)

Tolerances

Fexofenadine hydrochloride ($C_{32}H_{39}NO_4 \cdot HCl$):

NLT 80% (Q) of the labeled amount is dissolved.

Pseudoephedrine hydrochloride ($C_{10}H_{15}NO \cdot HCl$):

See *Table 7*.

Table 7

Time point (i)	Time (h)	Amount Dissolved (%)
1	0.5	NMT 35
2	2	45–65
3	4	60–80
4	12	NLT 80

The percentages of the labeled amount of pseudoephedrine hydrochloride, dissolved at the times specified, conform to *Dissolution* (711), *Acceptance Table 2*. • (RB 1-Apr-2016)

- **UNIFORMITY OF DOSAGE UNITS (905):** Meet the requirements

IMPURITIES

[NOTE—On the basis of knowledge of the product, perform either: (a) *Organic Impurities, Procedure 1* or (b) *Organic Impurities, Procedure 2*; *Organic Impurities, Procedure 3*; and *Organic Impurities, Procedure 4*.]

• ORGANIC IMPURITIES, PROCEDURE 1

Buffer, Mobile phase, Diluent, System suitability solution, Related compounds stock solution, Related compounds solution, Standard stock solution, Stan-

dard solution, and **Chromatographic system:** Proceed as directed in the *Assay, Procedure 1*.

Sample solution: Use the *Sample stock solution*, prepared as directed in the *Assay, Procedure 1*.

Reference solution: Use the *Sample solution*, prepared as directed in the *Assay, Procedure 1*.

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for pseudoephedrine and ephedrone are 1.0 and 1.2, respectively (*System suitability solution*); and for fexofenadine, fexofenadine related compound A, and decarboxylated degradant are 1.0, 1.2, and 3.1, respectively (*Standard solution*).]

Suitability requirements

Resolution: NLT 1.7 between pseudoephedrine and ephedrone, *System suitability solution*; NLT 2.0 between fexofenadine and fexofenadine related compound A, *Standard solution*

Relative standard deviation: NMT 1.0% for replicate injections based on the pseudoephedrine peak, *System suitability solution*; NMT 1.0% for replicate injections based on the fexofenadine peak and NMT 3.0% based on the individual peaks for fexofenadine related compound A and decarboxylated degradant, *Standard solution*

Analysis

Samples: *Sample solution* and *Reference solution*

Calculate the percentage of fexofenadine related compound A and decarboxylated degradant in the portion of Tablets taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = individual peak area response of either fexofenadine related compound A or decarboxylated degradant from the *Sample solution*

r_s = peak area response of fexofenadine related compound A or decarboxylated degradant from the *Standard solution*

C_s = concentration of either USP Fexofenadine Related Compound A RS or decarboxylated degradant in the *Standard solution* (mg/mL)

C_u = nominal concentration of fexofenadine hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of ephedrone in the portion of Tablets taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times (1/F) \times 100$$

r_u = peak height response of ephedrone from the *Sample solution*

r_s = peak height response of pseudoephedrine from the *Standard solution*

C_s = concentration of USP Pseudoephedrine Hydrochloride RS in the *Standard solution* (mg/mL)

C_u = nominal concentration of pseudoephedrine hydrochloride in the *Sample solution* (mg/mL)

F = relative response factor for ephedrone, 0.394
Calculate the percentage of any other impurities in the portion of Tablets taken:

$$\text{Result} = r_u / [(F \times r_s + r_t)] \times 100$$

r_u = individual peak area response of an individual unknown impurity from the *Sample solution*

- F = difference in concentration between the *Sample solution* and the *Reference solution*, 25
 r_s = peak area response of fexofenadine hydrochloride from the *Reference solution*
 r_T = sum of the peak area responses of all unknown impurities from the *Sample solution*

[NOTE—Disregard any peak below 0.05%.]
Acceptance criteria: See Table 8.

Table 8

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Pseudoephedrine	1.0	—
Fexofenadine	1.0	—
Ephedrone	1.2 ^a	0.2
Fexofenadine related compound A	1.2 ^b	0.4
Tertiary dehydrated impurity ^c	1.8	0.2
Decarboxylated degradant ^d	3.1 ^b	0.2
Any other individual impurity	—	0.2
Total impurities	—	0.8

^a Relative to pseudoephedrine.

^b Relative to fexofenadine.

^c 4-[4-(Diphenylmethylene)-1-piperidinyl]-1-hydroxybutyl]-2,2-dimethyl phenyl acetic acid.

^d (±)-4-(1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl)-isopropylbenzene.

• **ORGANIC IMPURITIES, PROCEDURE 2**

Solution A: Dissolve 2.7 g of monobasic potassium phosphate and 2.2 g of sodium 1-octanesulfonate in 1000 mL of water. Adjust with phosphoric acid to a pH of 2.50 ± 0.05.

Mobile phase: Methanol and *Solution A* (3:2)

Standard stock solution: 0.18 mg/mL of USP Fexofenadine Hydrochloride RS in *Mobile phase*

Standard solution: 0.0108 mg/mL of USP Fexofenadine Hydrochloride RS in *Mobile phase*, prepared from the *Standard stock solution*

Sensitivity solution: 0.54 µg/mL of USP Fexofenadine Hydrochloride RS in *Mobile phase*, prepared from the *Standard solution*

Sample solution: Weigh and finely powder 9 Tablets, and quantitatively transfer the ground powder to a 500-mL volumetric flask, with the aid of 200 mL of *Mobile phase*. Sonicate for 10 min, and add an additional 100 mL of *Mobile phase*. Shake by mechanical means for 30 min, and dilute with *Mobile phase* to volume. Pass a portion of the solution through a polypropylene or polysulfone membrane filter of 0.45-µm pore size, and discard at least the first 10 mL of the filtrate.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Flow rate: 1 mL/min

Injection volume: 20 µL

[NOTE—The run time is 6 times the retention time of fexofenadine.]

System suitability

Samples: *Standard solution* and *Sensitivity solution*

Suitability requirements

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution Analysis*

Samples: *Standard solution* and *Sample solution*
 Calculate the amount of each impurity as a percentage of the label claim of fexofenadine hydrochloride in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of individual impurities from the *Sample solution*

r_S = peak response of fexofenadine from the *Standard solution*

C_S = concentration of USP Fexofenadine Hydrochloride RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of fexofenadine hydrochloride in the *Sample solution* (mg/mL)

F = relative response factor for each impurity (see Table 9)

Acceptance criteria: See Table 9.

Table 9

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Fexofenadine	1.0	1.0	—
Meta fexofenadine	1.14	1.0	0.2
Fexofenadine related compound A	1.38	0.83	0.4
Tertiary dehydrated impurity ^a	2.25	1.3	0.2
Individual unspecified impurity	—	1.0	0.2
Total impurities	—	—	0.5

^a 4-[4-(Diphenylmethylene)-1-piperidinyl]-1-hydroxybutyl]-2,2-dimethyl phenyl acetic acid.

• **ORGANIC IMPURITIES, PROCEDURE 3**

Solution A: 4 mg/mL of ammonium acetate

Mobile phase: Methanol and *Solution A* (19:1)

Diluent: Methanol and water (1:1)

Standard stock solution: 0.18 mg/mL of USP Pseudoephedrine Hydrochloride RS in *Diluent*

Standard solution: 0.0216 mg/mL of USP Pseudoephedrine Hydrochloride RS in *Diluent*, prepared from the *Standard stock solution*

Sensitivity solution: 1.08 µg/mL of USP Pseudoephedrine Hydrochloride RS in *Diluent*, prepared from the *Standard solution*

Sample solution: Weigh and finely powder 9 Tablets, and quantitatively transfer the ground powder to a 500-mL volumetric flask, with the aid of 200 mL of *Diluent*. Sonicate for 10 min, and add an additional 100 mL of *Diluent*. Shake by mechanical means for 30 min, dilute with *Diluent* to volume, and mix. Pass a portion of the solution through a polypropylene or polysulfone membrane filter of 0.45-µm pore size, and discard at least the first 10 mL of the filtrate.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

8 Fexofenadine

Mode: LC
Detector: UV 215 nm
Column: 4.6-mm × 25-cm; 5-μm packing L3
Flow rate: 1 mL/min
Injection volume: 20 μL

System suitability

Samples: *Standard solution* and *Sensitivity solution*
Suitability requirements
Tailing factor: NMT 2.0, *Standard solution*
Relative standard deviation: NMT 5.0%, *Standard solution*
Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*
Calculate the amount of each impurity as a percentage of the label claim of pseudoephedrine hydrochloride in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

- r_U = peak response of individual impurities from the *Sample solution*
 r_S = peak response of pseudoephedrine from the *Standard solution*
 C_S = concentration of USP Pseudoephedrine Hydrochloride RS in the *Standard solution* (mg/mL)
 C_U = nominal concentration of pseudoephedrine hydrochloride in the *Sample solution* (mg/mL)
 F = relative response factor, equal to 0.52 for ephedrone (RRT, 0.85 relative to the pseudoephedrine peak) and 1 for all other impurities

Acceptance criteria

Individual impurities: NMT 0.2% for ephedrone; NMT 0.1% for any individual unspecified impurity

• ORGANIC IMPURITIES, PROCEDURE 4

Solution A: Dissolve 2.7 g of monobasic potassium phosphate and 2.2 g of sodium 1-octanesulfonate in 1000 mL of water. Adjust with phosphoric acid to a pH of 2.50 ± 0.05.

Solution B: Methanol and *Solution A* (2:3)

Solution C: Methanol and *Solution A* (7:3)

Mobile phase: See *Table 10*.

Table 10

Time (min)	Solution B (%)	Solution C (%)
0	100	0
40	100	0
41	0	100
65	0	100
66	100	0
90	100	0

Diluent: Methanol and water (1:1)

Standard stock solution: 0.18 mg/mL of USP Benzoic Acid RS in *Diluent*

Standard solution: 0.0216 mg/mL of USP Benzoic Acid RS in *Diluent*, prepared from the *Standard stock solution*

Sensitivity solution: 1.08 μg/mL of USP Benzoic Acid RS in *Diluent*, prepared from the *Standard solution*

Sample solution: Weigh and finely powder 9 Tablets, and quantitatively transfer the ground powder to a 500-mL volumetric flask, with the aid of 200 mL of *Diluent*. Sonicate for 10 min, and add an additional 100 mL of *Diluent*. Shake by mechanical means for 30

min, dilute with *Diluent* to volume, and mix. Pass a portion of the solution through a polypropylene or polysulfone membrane filter of 0.45-μm pore size, and discard at least the first 10 mL of the filtrate.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm × 25-cm; 5-μm packing L1

Flow rate: 1 mL/min

Injection volume: 10 μL

System suitability

Samples: *Standard solution* and *Sensitivity solution*

Suitability requirements

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the amount of each impurity as a percentage of the label claim of pseudoephedrine hydrochloride in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

- r_U = peak response of individual impurities from the *Sample solution*
 r_S = peak response of benzoic acid from the *Standard solution*
 C_S = concentration of USP Benzoic Acid RS in the *Standard solution* (mg/mL)
 C_U = nominal concentration of pseudoephedrine hydrochloride in the *Sample solution* (mg/mL)
 F = relative response factor for each impurity (see *Table 11*)

Acceptance criteria

Individual impurities: See *Table 11*.

Total impurities: The combined total impurities from *Procedure 3* and *Procedure 4* is NMT 0.3%.

Table 11

Name	Relative Retention Time	Relative Response Factor ^a	Acceptance Criteria, NMT(%)
Benzaldehyde	0.43	0.40	0.1
Benzoic acid	0.55	1.0	0.1
Ephedrone ^b	0.97	—	—
Pseudoephedrine	1.0	0.52	—
Individual unspecified impurity	—	0.52 ^c	0.1

^a Response factors relative to benzoic acid.

^b Ephedrone is not quantitated in this method. A separate method is used for the quantitation of this impurity.

^c The response factor of pseudoephedrine relative to that of benzoic acid is used in the calculation of individual unspecified impurities.

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE:** Preserve in well-closed containers, and store at controlled room temperature.
- LABELING:** When more than one *Dissolution Test* is given, the labeling states the test used only if *Test 1* is not used. If a test for *Organic Impurities* other than *Procedure 1* is used, the labeling states with which *Procedures* the article complies.

• **USP REFERENCE STANDARDS** <11>

- USP Benzoic Acid RS
- USP Fexofenadine Hydrochloride RS
- USP Fexofenadine Related Compound A RS
- Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]- α,α -dimethyl.

$C_{32}H_{37}NO_4$ 499.65
USP Pseudoephedrine Hydrochloride RS